{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:07Z","timestamp":1791327427750,"version":"4.3.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ctrv.2022.102479","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T11:21:35Z","timestamp":1666437695000},"page":"102479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Toxicities following CAR-T therapy for hematological malignancies"],"prefix":"10.1016","volume":"111","author":[{"given":"Rafael","family":"Hernani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Benzaqu\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2022.102479_b0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102479_b0015","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med [Internet]"},{"issue":"10254","key":"10.1016\/j.ctrv.2022.102479_b0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ctrv.2022.102479_b0025","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med [Internet]. 2020 Apr 1;382(14):1331\u201342. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1914347.","DOI":"10.1056\/NEJMoa1914347"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102479_b0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med [Internet]"},{"issue":"10297","key":"10.1016\/j.ctrv.2022.102479_b0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0040","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed\/Refractory Malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2022.102479_b0045","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T Cell Therapy for Cancer in the Clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0050","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther [Internet]"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102479_b0055","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102479_b0060","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood [Internet]"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102479_b0065","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol [Internet]"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102479_b0080","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102479_b0100","unstructured":"Gauthier J. Oral presentation. European Society for Blood and Marrow Transplantation. Virtual Meeting 14 - 17 March, 2021."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","article-title":"Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ctrv.2022.102479_b0110","article-title":"20;39(15_suppl):7532","author":"Gauthier","year":"2021","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0115","doi-asserted-by":"crossref","unstructured":"Galli E, Allain V, Di Blasi R, Bernard S, Vercellino L, Morin F, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma. Vol. 55, Bone marrow transplantation. England; 2020. p. 2347\u20139.","DOI":"10.1038\/s41409-020-01006-x"},{"key":"10.1016\/j.ctrv.2022.102479_b0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","author":"Li\u00e9vin","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2022.102479_b0125","doi-asserted-by":"crossref","unstructured":"Locke FL, Jacobson C, Ma L, Dong H, Hu Z-H, Siddiqi T, et al. Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood [Internet]. 2021 Nov 5;138(Supplement 1):530. Available from: https:\/\/doi.org\/10.1182\/blood-2021-149679.","DOI":"10.1182\/blood-2021-149679"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102479_b0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102479_b0135","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102479_b0140","doi-asserted-by":"crossref","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011 Aug;3(95):95ra73.","DOI":"10.1126\/scitranslmed.3002842"},{"key":"10.1016\/j.ctrv.2022.102479_b0145","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013 Mar;5(177):177ra38.","DOI":"10.1126\/scitranslmed.3005930"},{"key":"10.1016\/j.ctrv.2022.102479_b0150","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb;6(224):224ra25.","DOI":"10.1126\/scitranslmed.3008226"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102479_b0155","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"issue":"27","key":"10.1016\/j.ctrv.2022.102479_b0160","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ctrv.2022.102479_b0165","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102479_b0170","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102479_b0175","article-title":"The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic","volume":"12","author":"Sun","year":"2021","journal-title":"Review"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2022.102479_b0185","doi-asserted-by":"crossref","unstructured":"Sanderson R, Kuhnl A, Tholouli E, Menne TF, Patel A, Chaganti S, et al. CAR-T Toxicity Management and Steroid Use in High-Grade B-Cell Lymphoma: Impact on Real-World Survival Outcomes in the UK. Blood [Internet]. 2021 Nov 5;138(Supplement 1):531. Available from: https:\/\/doi.org\/10.1182\/blood-2021-149501.","DOI":"10.1182\/blood-2021-149501"},{"key":"10.1016\/j.ctrv.2022.102479_b0190","doi-asserted-by":"crossref","unstructured":"Park JH, Sauter CS, Palomba ML, Shah GL, Dahi PB, Lin RJ, et al. A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. Blood [Internet]. 2021 Nov 5;138(Supplement 1):96. Available from: https:\/\/doi.org\/10.1182\/blood-2021-150431.","DOI":"10.1182\/blood-2021-150431"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0195","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0200","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2022.102479_b0205","article-title":"13;134(Supplement_1):243","author":"Topp","year":"2019","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0210","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102479_b0215","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv [Internet]"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0220","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1080\/10428194.2020.1864349","article-title":"Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis","volume":"62","author":"Mian","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102479_b0225","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol [Internet]"},{"key":"10.1016\/j.ctrv.2022.102479_b0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Experimental hematology & oncology"},{"key":"10.1016\/j.ctrv.2022.102479_b0235","article-title":"5;138(Supplement 1):2816","author":"Gazeau","year":"2021","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0240","article-title":"5;138(Supplement 1):2812","author":"Wong","year":"2021","journal-title":"Available from:"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0245","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0250","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ctrv.2022.102479_b0255","doi-asserted-by":"crossref","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021 Nov;JCO2101992.","DOI":"10.1200\/JCO.21.01992"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102479_b0260","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematol","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol [Internet]"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102479_b0265","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102479_b0270","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0275","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0280","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102479_b0285","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2021004889","article-title":"Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma","volume":"5","author":"Jung","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0290","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2022.102479_b0295","unstructured":"DeAngelo DJ, Ghobadi A, Park JH et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study) [abstract]. J Immunother Cancer. 2017."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102479_b0300","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema","volume":"77","author":"Torre","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ctrv.2022.102479_b0305","article-title":"13;134(Supplement_1):2625","author":"Molostova","year":"2019","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0310","doi-asserted-by":"crossref","unstructured":"Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Brexucabtagene Autoleucel for Relapsed\/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. Blood [Internet]. 2021 Nov 5;138(Supplement 1):744. Available from: https:\/\/doi.org\/10.1182\/blood-2021-147563.","DOI":"10.1182\/blood-2021-147563"},{"key":"10.1016\/j.ctrv.2022.102479_b0315","article-title":"5;138(Supplement 1):1756","author":"Romancik","year":"2021","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0320","doi-asserted-by":"crossref","unstructured":"Dai M, Lin Y, El-Amouri SS, Kohls M, Pan D. Comprehensive evaluation of blood-brain barrier-forming micro-vasculatures: Reference and marker genes with cellular composition. PLoS One [Internet]. 2018 May 15;13(5):e0197379. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0197379.","DOI":"10.1371\/journal.pone.0197379"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0325","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102479_b0330","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102479_b0335","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0340","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0345","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ctrv.2022.102479_b0350","article-title":"7;130(Supplement 1):1547","author":"Locke","year":"2017","journal-title":"Available from:"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0355","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/neuonc\/noab174","article-title":"EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations","volume":"24","author":"Beuchat","year":"2022","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0360","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.ctrv.2022.102479_b0365","doi-asserted-by":"crossref","unstructured":"Banerjee R, Fakhri B, Shah N. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Leuk Lymphoma [Internet]. 2021 Jun 21;1\u201312. Available from: https:\/\/doi.org\/10.1080\/10428194.2021.1924370.","DOI":"10.1080\/10428194.2021.1924370"},{"issue":"138","key":"10.1016\/j.ctrv.2022.102479_b0370","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2021-147403","article-title":"Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed\/Refractory Large B-Cell Lymphoma (R\/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)","volume":"5","author":"Oluwole","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0375","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2022.102479_b0380","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-135988","article-title":"ZUMA-19: A Phase 1\/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R\/R LBCL)","volume":"136","author":"Kenderian","year":"2020","journal-title":"Blood [Internet]"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102479_b0385","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102479_b0390","article-title":"5;138(Supplement 1):1744","author":"Maakaron","year":"2021","journal-title":"Available from:"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0395","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.1987.5.2.202","article-title":"Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia","volume":"5","author":"Balis","year":"1987","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0400","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier","volume":"55","author":"Gutierrez","year":"1994","journal-title":"J Neuroimmunol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102479_b0405","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv [Internet]"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001114","article-title":"Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2","volume":"8","author":"Wang","year":"2020","journal-title":"J Immunother cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102479_b0415","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102479_b0420","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102479_b0425","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2022.102479_b0430","article-title":"New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2022.102479_b0435","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed\/refractory large B-cell lymphoma","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0445","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0450","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102479_b0455","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2022.102479_b0460","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Iacoboni G, Penack O, B\u00fccklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer [Internet]. 2022 May 1;10(5):e004475. Available from: http:\/\/jitc.bmj.com\/content\/10\/5\/e004475.abstract.","DOI":"10.1136\/jitc-2021-004475"},{"key":"10.1016\/j.ctrv.2022.102479_b0465","doi-asserted-by":"crossref","unstructured":"Kiem D, Leisch M, Neureiter D, Haslauer T, Egle A, Melchardt T, et al. Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. Vol. 22, International journal of molecular sciences. 2021.","DOI":"10.3390\/ijms22115449"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102479_b0470","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report","volume":"9","author":"Baur","year":"2021","journal-title":"J Immunother cancer"},{"key":"10.1016\/j.ctrv.2022.102479_b0475","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2022.102479_b0480","first-page":"2","article-title":"CD34 Seleceted Stem Cell Boost Can Safely Improve Cytopaenias Following CAR-T Therapy","volume":"P111","author":"Mullanfiroze","year":"2022","journal-title":"EBMT"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0485","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1703124","article-title":"Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation","volume":"28","author":"Demirkazik","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"9967","key":"10.1016\/j.ctrv.2022.102479_b0490","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102479_b0495","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"7897","key":"10.1016\/j.ctrv.2022.102479_b0500","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature [Internet]"},{"key":"10.1016\/j.ctrv.2022.102479_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102479_b0510","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions","volume":"10","author":"Wat","year":"2022","journal-title":"J allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0515","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13075-016-1152-5","article-title":"Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"18","author":"Lavielle","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102479_b0520","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102479_b0525","article-title":"Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma in the United States","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0530","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102479_b0535","doi-asserted-by":"crossref","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open forum Infect Dis [Internet]. 2020 Apr 9;7(5):ofaa121\u2013ofaa121. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32432149.","DOI":"10.1093\/ofid\/ofaa121"},{"key":"10.1016\/j.ctrv.2022.102479_b0540","article-title":"Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium","volume":"5;138(Supplement 1):3826","author":"Spiegel","year":"2021","journal-title":"Blood [Internet]"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102479_b0545","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ctrv.2022.102479_b0550","doi-asserted-by":"crossref","unstructured":"Garner W, Samanta P, Haidar G. Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions. J fungi (Basel, Switzerland). 2021 Feb;7(2).","DOI":"10.3390\/jof7020156"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102479_b0555","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","article-title":"Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed\/Refractory Large B Cell Lymphoma","volume":"26","author":"Oluwole","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0560","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","article-title":"The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma","volume":"22","author":"Cao","year":"2020","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102479_b0565","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv [Internet]"},{"key":"10.1016\/j.ctrv.2022.102479_b0570","article-title":"5;138(Supplement 1):2512","author":"Riedell","year":"2021","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855730","article-title":"Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO\/GETH Spanish Groups [Internet]","volume":"Vol. 13","author":"Bastos-Oreiro","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102479_b0580","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","author":"Kwon","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2022.102479_b0585","doi-asserted-by":"crossref","unstructured":"Luo H, Wang N, Huang L, Zhou X, Jin J, Li C, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer [Internet]. 2019;7(1):271. Available from: https:\/\/doi.org\/10.1186\/s40425-019-0767-x.","DOI":"10.1186\/s40425-019-0767-x"},{"key":"10.1016\/j.ctrv.2022.102479_b0590","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","author":"Beyar-Katz","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2022.102479_b0595","doi-asserted-by":"crossref","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021 Apr;49(2):215\u201331.","DOI":"10.1007\/s15010-020-01521-5"},{"key":"10.1016\/j.ctrv.2022.102479_b0600","unstructured":"Pe\u00f1a-Mu\u00f1oz F, Mart\u00edn L\u00f3pez A, P\u00e9rez-L\u00f3pez E, Cabero-Mart\u00ednez A, Prieto-Garc\u00eda L, Garc\u00eda Bl\u00e1zquez M, et al. CMV reactivation in patients treated with CAR-T cell therapies: Single center experience. 4th European CAR T-cell Meeting. 2022."},{"key":"10.1016\/j.ctrv.2022.102479_b0605","unstructured":"M\u00e1rquez-Algaba E, Pernas B, Esperalba J, Los-Arcos I, Carpio C, Iacoboni G, et al. Cytomegalovirus Impact in B-cell Lymphoma Patients Treated with Chimeric Antigen Receptor T-cell Therapy. P101 EBMT. 2022."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0610","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102479_b0615","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Westin JR, Miklos DB, Herrera AF, Lee J, Seng J, et al. Phase 1\/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL). Presented at: 2020 American Association for Cancer . In 2020.","DOI":"10.1158\/1538-7445.AM2020-CT055"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102479_b0620","doi-asserted-by":"crossref","first-page":"13071684","DOI":"10.3390\/cancers13071684","article-title":"Infection complications after lymphodepletion and dosing of chimeric antigen receptor t (Car-t) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or b cell non-hodgkin lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102479_b0625","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious Complications of CAR T-Cell Therapy Across Novel Antigen Targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102479_b0630","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.ctrv.2022.102479_b0635","article-title":"Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102479_b0640","doi-asserted-by":"crossref","unstructured":"Wei J, Zhu X, Mao X, Huang L, Meng F, Zhou J. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer [Internet]. 2019 Dec 1;7(1):315. Available from: http:\/\/jitc.bmj.com\/content\/7\/1\/315.abstract.","DOI":"10.1186\/s40425-019-0790-y"},{"key":"10.1016\/j.ctrv.2022.102479_b0645","article-title":"Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive","volume":"Vol. 12","author":"Ma","year":"2021","journal-title":"Therapy"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102479_b0650","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","article-title":"Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study","volume":"28","author":"Gibson","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2022.102479_b0655","first-page":"3692","volume":"Vol. 125","author":"Abramson","year":"2019","journal-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma"},{"key":"10.1016\/j.ctrv.2022.102479_b0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"Journal of hematology & oncology"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102479_b0665","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41409-020-01018-7","article-title":"Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations","volume":"56","author":"Allred","year":"2020","journal-title":"Bone Marrow Transplant [Internet]"},{"key":"10.1016\/j.ctrv.2022.102479_b0670","article-title":"8;6(11)","author":"Walti","year":"2021","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0675","doi-asserted-by":"crossref","unstructured":"Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, et al. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv\u00a0: the preprint server for health sciences. 2021.","DOI":"10.1101\/2021.05.10.21256634"},{"key":"10.1016\/j.ctrv.2022.102479_b0680","doi-asserted-by":"crossref","unstructured":"Maus M V, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer [Internet]. 2020 Dec 1;8(2):e001511. Available from: http:\/\/jitc.bmj.com\/content\/8\/2\/e001511.abstract.","DOI":"10.1136\/jitc-2020-001511"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102479_b0685","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0690","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0695","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe [Internet]"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102479_b0700","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2022.102479_b0710","doi-asserted-by":"crossref","unstructured":"Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Ghobadi A, Komanduri K V, et al. Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood [Internet]. 2019 Nov 13;134(Supplement_1):764. Available from: https:\/\/doi.org\/10.1182\/blood-2019-124750.","DOI":"10.1182\/blood-2019-124750"},{"key":"10.1016\/j.ctrv.2022.102479_b0715","doi-asserted-by":"crossref","unstructured":"Jacobson C, Locke FL, Ghobadi A, Miklos DB. 1764 Long-Term (4- and 5-Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL). 63rd ASH Annu Meet Expo December 11-14, 2021. 2021;2020.","DOI":"10.1182\/blood-2021-148078"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102479_b0720","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood [Internet]"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0725","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncology"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102479_b0730","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular Toxicities of CAR T-cell Therapy","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2022.102479_b0735","doi-asserted-by":"crossref","unstructured":"Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Dis (Basel, Switzerland). 2021 Mar;9(1).","DOI":"10.3390\/diseases9010020"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0740","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood [Internet]"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102479_b0745","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The Tumor Lysis Syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.ctrv.2022.102479_b0750","doi-asserted-by":"crossref","first-page":"9684909","DOI":"10.1155\/2017\/9684909","article-title":"Tumor Lysis Syndrome in Patients with Hematological Malignancies","volume":"2017","author":"Belay","year":"2017","journal-title":"J Oncol"},{"key":"10.1016\/j.ctrv.2022.102479_b0755","doi-asserted-by":"crossref","unstructured":"Palomba ML, Gordon LI, Siddiqi T, Abramson JS, Kamdar M, Lunning MA, et al. Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. Blood [Internet]. 2020 Nov 5;136(Supplement 1):10\u20131. Available from: https:\/\/doi.org\/10.1182\/blood-2020-136158.","DOI":"10.1182\/blood-2020-136158"},{"key":"10.1016\/j.ctrv.2022.102479_b0760","article-title":"Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2022.102479_b0765","series-title":"Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation","author":"Gabelli","year":"2021"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102479_b0770","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102479_b0775","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.bbmt.2020.04.025","article-title":"Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"26","author":"Schubert","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2022.102479_b0780","doi-asserted-by":"crossref","unstructured":"Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, et al. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large B-cell lymphoma. Vol. 192, British journal of haematology. England; 2021. p. 212\u20136.","DOI":"10.1111\/bjh.17121"},{"key":"10.1016\/j.ctrv.2022.102479_b0785","article-title":"1;7(Supplement_1):S354\u2013S354","author":"Tran","year":"2020","journal-title":"Available from:"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102479_b0790","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2022.102479_b0795","doi-asserted-by":"crossref","unstructured":"Shouse G, Kaempf A, Yashar D, Sigmund AM, Smilnak G, Bair SM, et al. Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. Blood [Internet]. 2021 Nov 5;138(Supplement 1):529. Available from: https:\/\/doi.org\/10.1182\/blood-2021-149735.","DOI":"10.1182\/blood-2021-149735"},{"key":"10.1016\/j.ctrv.2022.102479_b0800","doi-asserted-by":"crossref","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, et al. CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity. Blood Adv [Internet]. 2021 Jul 15;5(14):2799\u2013806. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2021004575.","DOI":"10.1182\/bloodadvances.2021004575"},{"key":"10.1016\/j.ctrv.2022.102479_b0805","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102479_b0810","doi-asserted-by":"crossref","first-page":"242.e1","DOI":"10.1016\/j.jtct.2020.12.025","article-title":"Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma","volume":"27","author":"Mirza","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0815","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.ctrv.2022.102479_b0820","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv [Internet]"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102479_b0825","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2022.102479_b0830","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016 Sep;8(355):355ra116.","DOI":"10.1126\/scitranslmed.aaf8621"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102479_b0835","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102479_b0840","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2022.102479_b0845","doi-asserted-by":"crossref","unstructured":"Tedesco VE 5th, Mohan C. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. J Immunol. 2021 Apr;206(7):1561\u20138.","DOI":"10.4049\/jimmunol.2001249"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102479_b0850","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.ctrv.2022.102479_b0855","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102479_b0860","doi-asserted-by":"crossref","unstructured":"Nahas GR, Komanduri K V., Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma [Internet]. 2020;61(4):940\u20133. Available from: https:\/\/doi.org\/10.1080\/10428194.2019.1697814.","DOI":"10.1080\/10428194.2019.1697814"},{"key":"10.1016\/j.ctrv.2022.102479_b0865","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/sci-2021-008","article-title":"Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting","volume":"8","author":"Thakkar","year":"2021","journal-title":"Stem cell Investig"},{"key":"10.1016\/j.ctrv.2022.102479_b0870","doi-asserted-by":"crossref","unstructured":"Zhu F, Wei G, Liu Y, Zhou H, Wu W, Yang L, et al. Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed\/Refractory B-cell Malignancies. Cell Transplant. 2021;30:9636897211025504.","DOI":"10.1177\/09636897211025503"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102479_b0875","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2022.102479_b0880","article-title":"5;138(Supplement 1):3861","author":"Korell","year":"2021","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2022.102479_b0885","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102479_b0890","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102479_b0895","doi-asserted-by":"crossref","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood [Internet]. 2017\/04\/13. 2017 Jun 22;129(25):3322\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28408462.","DOI":"10.1182\/blood-2017-02-769208"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102479_b0900","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102479_b0905","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102479_b0910","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071684","article-title":"Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102479_b0915","article-title":"Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol [Internet]"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102479_b0920","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102479_b0925","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102479_b0930","series-title":"Tandem Meetings (Transplantation % Cellular Therapy Meetings of ASTCT and CIBMTR)","article-title":"Early Versus Standard Management of CAR T-Cell Therapy Related Toxicities: A Single Center Experience. Poster 236","author":"Gaffney","year":"2022"},{"key":"10.1016\/j.ctrv.2022.102479_b0935","doi-asserted-by":"crossref","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J [Internet]. 2020;10(2):15. Available from: https:\/\/doi.org\/10.1038\/s41408-020-0280-y.","DOI":"10.1038\/s41408-020-0280-y"},{"key":"10.1016\/j.ctrv.2022.102479_b0940","doi-asserted-by":"crossref","unstructured":"Frigault MJ, Gallagher KME, Wehrli M, Valles B, Casey K, Lindell K, et al. A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity. Blood [Internet]. 2021 Nov 5;138(Supplement 1):2814. Available from: https:\/\/doi.org\/10.1182\/blood-2021-146927.","DOI":"10.1182\/blood-2021-146927"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:10Z","timestamp":1759656490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":188,"alternative-id":["S0305737222001487"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102479","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicities following CAR-T therapy for hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102479"}}